
Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

How do you feel about this ipt?
Relieva is a proprietary cannabis and hemp-derived pre-roll blend formulated for pain relief. Using New Leaf’s unique strain portfolio, it standardizes cannabinoid and terpene compositions to deliver consistent, therapeutic formulations for targeted wellness applications.
Current cannabis products lack standardized, scientifically validated formulations for pain relief. Consumers face inconsistent effects and limited access to compliant, data-driven solutions that bridge the gap between medical efficacy and wellness-oriented use.
Relieva pioneers functional, compliant cannabis formulations that combine plant science and technology to deliver consistent pain relief. By leveraging automated production and proprietary blends, it positions itself to lead the $125B global wellness cannabis market.
Relieva is a proprietary cannabis and hemp-derived pre-roll blend formulated for pain relief. Using New Leaf’s unique strain portfolio, it standardizes cannabinoid and terpene compositions to deliver consistent, therapeutic formulations for targeted wellness applications.
Current cannabis products lack standardized, scientifically validated formulations for pain relief. Consumers face inconsistent effects and limited access to compliant, data-driven solutions that bridge the gap between medical efficacy and wellness-oriented use.
Relieva pioneers functional, compliant cannabis formulations that combine plant science and technology to deliver consistent pain relief. By leveraging automated production and proprietary blends, it positions itself to lead the $125B global wellness cannabis market.
The project captures value by issuing tokens that grant holders fractional rights to revenue generated from intellectual property licensing. These tokens entitle users to a share of royalty streams, aligning incentives between IP creators and token holders.
Additionally, token ownership provides privileged access to data rooms, research and development updates, and opportunities for exclusive licensing. This model not only monetizes IP assets but also fosters a community of engaged stakeholders who benefit directly from the project’s commercial success.
Phase I — Research & Formulation
Identify target outcomes and map active compound combinations
Phase II — Pilot Manufacturing
Produce small batches for lab and sensory testing under regulatory standards
Phase III — IP Protection
File patents and trademarks for novel formulations, processes, and branding
Phase IV — Brand & Regulatory Positioning
Establish compliant wellness product positioning with FDA and other regulators
Phase V — Market Testing
Soft launch via pilot retail or e-commerce channels to gather consumer insights and early revenues

https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13345

https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-023-00207-7

https://www.painphysicianjournal.com/linkout?issn=&vol=20&page=E755

https://journals.lww.com/behaviouralpharm/abstract/2022/04000/antinociceptive_effects_of_minor_cannabinoids,.5.aspx
No announcements yet
Come back at a later point
Get the latest community updates and find out about upcoming Relieva developments